KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113.

Mao Okada, Eiichiro Suzuki, Chigusa Morizane, Gakuto Ogawa, Yusuke Sano, Hiroshi Imaoka, Satoshi Kobayashi, Masafumi Ikeda, Naohiro Okano, Haruo Miwa, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Sohei Satoi, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Kenkichi Masutomi, Takuji Okusaka, Masato Ozaka, Makoto Ueno, members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)

Jpn J Clin Oncol 55(6) 594-602

PMID40052520
PMCIDPMC12138772
DOI10.1093/jjco/hyaf035
发表日期2025-03-07
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图。
摘要

摘要

BACKGROUND: The JCOG1113, a multicenter, randomized phase III trial in patients with advanced/recurrent biliary tract cancer showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin. Although liver cirrhosis (LC) is a known risk factor for intrahepatic cholangiocarcinoma (ICC), few reports focus on the efficacy and safety of chemotherapy in ICC patients with LC. METHODS: We performed a subgroup analysis of ICC patients enrolled in the JCOG1113. The presence or absence of LC was evaluated based on clinical factors such as radiographic findings, medical history, laboratory data, and physical examination at enrollment. We evaluated differences in the safety and efficacy of chemotherapy according to the presence or absence of clinically diagnosed LC. RESULTS: Of the 94 eligible patients with ICC, 10 were clinically diagnosed with LC. In the non-LC/clinically diagnosed LC group, grade 3 or 4 neutropenia, anemia, decreased platelet count, and non-hematological adverse events were observed in 51.2%/60%, 15.5%/0%, 11.9%/40%, and 38.1%/30% patients. The median overall survival was 13.7 months in the non-LC group and 19.0 months in the clinically diagnosed LC group (hazard ratio [HR]: 0.969, 95% confidence interval [CI]: 0.482-1.948). The median progression-free survival was 5.9 months in the non-LC group and 7.1 months in the clinically diagnosed LC group (HR, 0.995; 95% CI, 0.513-1.929). CONCLUSION: The results of this study indicated that eligible ICC patients with clinically diagnosed LC, as determined by clinical and CT imaging findings, did not exhibit any apparent safety or efficacy disadvantage compared to those without LC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Comparison of overall survival and progression-free survival in clinically diagnosed liver cirrhosis and non- liver cirrhosis groups.
非 KM Figure
Figure 2Overall survival comparison of gemcitabine plus cisplatin (GC) and gemcitabine plus S-1 (GS) in non-liver cirrhosis group and clinically diagnosed liver cirrhosis group.
非 KM Figure